Approval Year
Substance Class |
Structurally Diverse
Created
by
admin
on
Edited
Sat Dec 16 15:18:32 GMT 2023
by
admin
on
Sat Dec 16 15:18:32 GMT 2023
|
Source Materials Class | ORGANISM |
Source Materials Type | BACTERIUM |
Source Materials State | LIVE |
Organism Family | Staphylococcaceae |
Organism Genus | Staphylococcus |
Organism Species | aureus |
Author | ROSENBACH, 1884 |
Infraspecific Type | STRAIN |
Infraspecific Name | METHICILLIN RESISTANCE |
Part | WHOLE |
Record UNII |
65P5WPF3BJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
65P5WPF3BJ
Created by
admin on Sat Dec 16 15:18:36 GMT 2023 , Edited by admin on Sat Dec 16 15:18:36 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
Efficacy and safety profiles of both dalbavancin and oritavancin were the same as vancomycin in the treatment of gram-positive bacterial infections in different clinical settings,
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
PRECLINICAL
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
Efficacy and safety profiles of both dalbavancin and oritavancin were the same as vancomycin in the treatment of gram-positive bacterial infections in different clinical settings,
|
||
|
INHIBITOR->TARGET ORGANISM |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MIC | BIOLOGICAL |
|
AGENT: FOSFOMYCIN |
|
||